Is PASI 100 the new benchmark in psoriasis?

KAUAI, HAWAII – “I think we should just do away with PASI 90 and look at how well our drugs do against the metric of PASI 100.”

How to avoid severe diarrhea from apremilast

Delayed up-titration of apremilast is often effective, albeit at cost of slower efficacy.

Dermatology practice gaps: improving medication management

KAUAI, HAWAII – Ophthalmologists’ hydroxychloroquine dosing recommendations to avoid retinopathy have changed.

Here comes bimekizumab, the newest IL-17 inhibitor

KAUAI, HAWAII – “If this holds up in phase 3, it’s going to be a new world for our patients and for us, ” said Craig L. Leonardi, MD.

Get ready for certolizumab for psoriasis

KAUAI, HAWAII – Women of childbearing potential may prefer it.

Make a PEST of your psoriasis patients

KAUAI, HAWAII – Every psoriasis patient should complete the Psoriasis Epidemiology Screening Tool (PEST) for psoriatic arthritis annually.

Immunogenicity concerns for biosimilars so far don’t go beyond originator biologics

But there are few data available on the impact of antidrug antibodies to biosimilars across rheumatic diseases and on switching.

Early ankylosing spondylitis treatment stops transition from inflammatory to bone-forming fatty lesions

“The earlier we treat intensively, the better impact you have on structural outcomes,” according to Dirk Elewaut, MD, PhD.

‘Multimorbidities’ in RA make impact on treatment efficacy, disease activity

The effects of two or more chronic conditions in patients with RA, such as obesity, fibromyalgia, depression, and anxiety, need to be considered in patient management.

Study: TNF inhibitors improve extraintestinal IBD manifestations

SAN DIEGO – Tumor necrosis factor inhibitors improved the extraintestinal manifestations of inflammatory bowel disease (IBD) among more than half of affected patients, according to a national cohort study. “The best response rates were for...

Pages